Press Releases | Alexion Pharmaceuticals, Inc

About Alexion
Patient Focus
Products
Research & Development
Responsibility
Careers
Select a Country
- North America
  - Canada
  - USA
- Latin America
  - Argentina
  - Brazil
  - Colombia
  - Mexico
- Europe, the Middle East & Africa
  - Alexion Europe
  - Belgium
  - Denmark
  - France
  - Germany
  - Ireland
  - Italy
  - Netherlands
  - Norway
  - Russia
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - UAE
  - UK
- Asia Pacific
  - Australia
  - China
  - India
  - Japan
Investors
News
Contact

Home
»
Newsroom
»
Press Releases

Press Releases

All News Releases

Alexion Announces Appointment of Tanisha Carino, Ph.D., as Chief Corporate Affairs Officer
October 10, 2019
HTML PDF
Alexion and Stealth Announce Agreement for Option to Co-Develop and Commercialize Late-Stage Therapy for Mitochondrial Diseases
October 10, 2019
HTML PDF
Alexion Announces CFO Succession
September 17, 2019
HTML PDF
Alexion and BridgeBio Announce Japanese License Agreement for Eidos’ Transthyretin Amyloidosis (ATTR) Investigational Medicine
September 9, 2019
HTML PDF
Alexion to Present at the 17th Annual Morgan Stanley Global Healthcare Conference
September 4, 2019
HTML PDF
Alexion Announces Upcoming Data Presentations at 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
August 28, 2019
HTML PDF
European Commission Approves SOLIRIS® (eculizumab) For the Treatment of Adults with Neuromyelitis Optica Spectrum Disorder (NMOSD)
August 27, 2019
HTML PDF
Alexion Receives Positive CHMP Opinion for SOLIRIS® (eculizumab) for the Treatment of NMOSD
July 26, 2019
HTML PDF
Alexion Reports Second Quarter 2019 Results
July 24, 2019
HTML PDF
Alexion to Report Second Quarter 2019 Results On Wednesday, July 24, 2019
July 10, 2019
HTML PDF